Last quarter (Q ), Eloxx Pharmaceuticals's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q, Eloxx Pharmaceuticals's net income was $-7.51M. See Eloxx Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 21	Dec 20	Dec 19	Dec 18	Dec 17
Total Revenue	-	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 40.02M	$ 66.02M	$ 29.44M	$ 50.55M	$ 46.97M	$ 19.10M
Operating Income	$ -40.02M	$ -66.02M	$ -29.44M	$ -50.55M	$ -46.97M	$ -19.10M
Net Non Operating Interest Income Expense	$ -1.72M	$ -1.25M	$ -1.07M	$ -544.00K	$ 594.00K	$ -668.00K
Other Income Expense	$ -96.00K	$ 542.00K	$ -4.07M	$ 225.00K	$ -686.00K	$ -1.45M
Pretax Income	$ -41.84M	$ -66.73M	$ -34.58M	$ -50.87M	$ -47.06M	$ -21.21M
Tax Provision	-	-	$ 0.00	$ 0.00	$ 122.00K	$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -41.84M	$ -66.73M	$ -34.58M	$ -50.87M	$ -47.19M	$ -23.62M
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 40.02M	$ 66.02M	$ 29.44M	$ 50.55M	$ 46.97M	$ 19.10M
Net Income From Continuing And Discontinued Operation	$ -41.84M	$ -66.73M	$ -34.58M	$ -50.87M	$ -47.19M	$ -21.21M
Normalized Income	$ -41.74M	$ -67.27M	$ -30.51M	$ -51.10M	$ -46.68M	$ -19.77M
Interest Expense	$ 1.82M	$ 1.26M	$ 1.41M	$ 1.62M	$ 7.00K	$ 43.00K
EBIT	$ -40.01M	$ -65.47M	$ -33.17M	$ -49.26M	$ -47.06M	$ -21.17M
EBITDA	$ -39.29M	$ -64.51M	$ -32.60M	$ -48.70M	$ -46.84M	$ -21.13M

Currency in USD

Eloxx Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing